Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Safety, Pharmacokinetic, and Immunologic Study to Evaluate CDX-301 (rhuFlt3L) in Healthy Volunteers

NCT01465139 is registered in ClinicalTrials.gov with Celldex Therapeutics as lead sponsor.

NCT NCT01465139
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01465139 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Safety, Pharmacokinetic, and Immunologic Study to Evaluate CDX-301 (rhuFlt3L) in Healthy Volunteers
Lead sponsor
Celldex Therapeutics
Phase
Phase 1
Overall status
Completed
Start date
October 31, 2011
Completion date
January 31, 2013
Enrollment
30 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

healthy